Giuseppe Floris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8325955/publications.pdf

Version: 2024-02-01

158	7,756	109264	56687
papers	citations	35 h-index	83 g-index

165	165	165	12974
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Papillary lesions of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 65-84.	1.4	22
2	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
3	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). Cancer Research, 2022, 82, P1-02-09-P1-02-09.	0.4	0
4	Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. Cancer Research, 2022, 82, P3-09-18-P3-09-18.	0.4	0
5	Abstract P4-02-02: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. Cancer Research, 2022, 82, P4-02-02-P4-02-02.	0.4	0
6	Abstract P3-08-07: Comparison of the genomic alterations in metastatic inflammatory and non-inflammatory breast cancer. Cancer Research, 2022, 82, P3-08-07-P3-08-07.	0.4	0
7	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	1.3	19
8	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Annals of Oncology, 2022, 33, 769-785.	0.6	37
9	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. British Journal of Cancer, 2022, 127, 988-1013.	2.9	30
10	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 146-153.	3.0	31
11	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	2.9	5
12	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2â˜' early breast cancer. Modern Pathology, 2021, 34, 1297-1309.	2.9	5
13	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. Scientific Reports, 2021, 11, 3176.	1.6	17
14	Cancer and Aging: Two Tightly Interconnected Biological Processes. Cancers, 2021, 13, 1400.	1.7	83
15	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nature Medicine, 2021, 27, 820-832.	15.2	330
16	Correlation of Trop-2 expression with clinicopathological characteristics, sTILs, AR expression and outcome in primary TNBC.. Journal of Clinical Oncology, 2021, 39, e12558-e12558.	0.8	3
17	The MNK1/2â€“eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. Cancer Research, 2021, 81, 3876-3889.	0.4	21
18	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. EClinicalMedicine, 2021, 35, 100856.	3.2	42

#	Article	IF	Citations
19	Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer. Cancers, 2021, 13, 2185.	1.7	2
20	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. Cancers, 2021, 13, 3695.	1.7	35
21	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	2.9	14
22	Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers, 2021, 13, 4410.	1.7	8
23	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. European Journal of Cancer, 2021, 155, 13-24.	1.3	7
24	Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. Npj Breast Cancer, 2021, 7, 128.	2.3	2
25	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers, 2021, 13, 4910.	1.7	8
26	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	0.5	2
27	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1041-1048.	1.2	1
28	Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 185, 183-194.	1.1	14
29	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	2.9	25
30	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
31	Ageâ€related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer. Clinical and Translational Immunology, 2020, 9, e1184.	1.7	24
32	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Research and Treatment, 2020, 183, 759-770.	1.1	16
33	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. Clinical Chemistry, 2020, 66, 1414-1423.	1.5	9
34	Digital analysis of distant and cancer-associated mammary adipocytes. Breast, 2020, 54, 179-186.	0.9	5
35	Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration. International Journal of Medical Sciences, 2020, 17, 2269-2275.	1.1	5
36	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical featuresÂin invasive micropapillary breast carcinoma with long-term outcomes. Breast Cancer Research and Treatment, 2020, 184, 985-998.	1.1	9

#	Article	IF	Citations
37	Gold Nanoparticles: A New Golden Era in Oncology?. Pharmaceuticals, 2020, 13, 192.	1.7	30
38	67P Digital analysis of distant and cancer-associated adipocytes in breast cancer. Annals of Oncology, 2020, 31, S37-S38.	0.6	0
39	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
40	A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Research, 2020, 30, 745-762.	5.7	391
41	Behavior of metastatic breast cancer according to subtype. Breast Cancer Research and Treatment, 2020, 181, 115-125.	1.1	32
42	Fibromatosis-like metaplastic carcinoma: a case report and review of the literature. Diagnostic Pathology, 2020, 15, 20.	0.9	15
43	Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. Histopathology, 2020, 77, 79-91.	1.6	33
44	Granulomatosis with polyangiitis with breast involvement mimicking metastatic cancer: Case report and literature review. European Journal of Rheumatology, 2020, 7, 41-43.	1.3	6
45	Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study. , 2020, , .		0
46	Abstract P3-07-14: Multigene signatures based risk estimates in early ER+/HER2- breast cancer: The predictive value of inexpensive statistical models and changes in adjuvant chemotherapy use. , 2020, , .		0
47	Abstract P1-10-04: Impact of body mass index (BMI) on the predictive and prognostic value of stromal tumor-infiltrating lymphocytes (sTIL) in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NACT). , 2020, , .		0
48	Abstract P6-10-13: Associated ductal carcinoma in situ in primary operated TNBC is associated with a longer time to distant event. , 2020, , .		0
49	Abstract P3-08-26: Clinico-pathological characteristics of metaplastic breast cancer as compared to normal TNBC: A single center analysis. , 2020, , .		0
50	Abstract P5-06-08: Predicting distant recurrence of ER+ HER2- breast cancer after 5 years of endocrine therapy: The CTS5-tool validation in real life. , 2020, , .		0
51	Abstract P5-04-23: Characterization of the tumor microenvironment in a large series of ER/PR negative breast cancer. , 2020, , .		0
52	Abstract P3-08-31: Clinical and pathological features of invasive micropapillary carcinoma of the breast and correlation with prognosis. , 2020, , .		0
53	Abstract P5-06-28: Optimization and validation ofPIK3CAmutation detection with droplet digital PCR in liquid biopsies of patients with metastatic breast cancer. , 2020, , .		1
54	Abstract P6-08-03: Germline mutational landscape in 5422 individuals at risk for hereditary breast and ovarian cancer who underwent multi-gene panel testing. , 2020, , .		0

#	Article	IF	Citations
55	Abstract P1-10-07: The presence of ductal carcinoma in situ in core needle biopsy and microcalcifications on mammography in TNBC is associated with a lower pCR and worse long term outcome. , 2020, , .		0
56	Abstract P2-14-23: Outcome of patients with triple-negative breast cancer who did not receive adjuvant chemotherapy. , 2020, , .		0
57	Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. Cell Metabolism, 2019, 30, 917-936.e10.	7.2	150
58	Decentralization of Next-Generation RNA Sequencing-Based MammaPrintÂ® and BluePrintÂ® Kit at University Hospitals Leuven and Curie Institute Paris. Translational Oncology, 2019, 12, 1557-1565.	1.7	6
59	Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling. Annals of Oncology, 2019, 30, iii45.	0.6	1
60	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. Breast Cancer Research and Treatment, 2019, 176, 699-708.	1.1	22
61	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 867-871.	3.0	41
62	Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty. Annals of Oncology, 2019, 30, xi49.	0.6	0
63	DETAILED ANALYSIS OF TUMOR INFILTRATING LYMPHOCYTES IN THREE AGE CATEGORIES OF BREAST CANCER PATIENTS: CORRELATION WITH SYSTEMIC IMMUNOSENESCENCE/FRAILTY MARKERS. Journal of Geriatric Oncology, 2019, 10, S120-S121.	0.5	0
64	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. Oncologist, 2019, 24, 165-171.	1.9	23
65	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. European Journal of Surgical Oncology, 2019, 45, 550-559.	0.5	14
66	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. Breast Cancer Research and Treatment, 2019, 174, 55-63.	1.1	3
67	Abstract P5-09-05: Hereditary breast cancer beyond BRCA: Clinical and histopathological characteristics in patients with germline CHEK2, ATM, PALB2 and TP53-mutations. , 2019, , .		1
68	Abstract P3-03-32: Monocentric experience with the sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically lymph node negative early breast cancer. , 2019, , .		0
69	The prognostic role of the androgen receptor in patients with triple-negative early breast cancers and primary surgery.. Journal of Clinical Oncology, 2019, 37, e12042-e12042.	0.8	0
70	Abstract 1406: Multigene signatures based risk estimates in ER+/HER2- breast cancers: The predictive value of inexpensive statistical models and changes in adjuvant chemotherapy use. , 2019, , .		0
71	Breast cancer subtype and survival by parity and time since last birth. Breast Cancer Research and Treatment, 2018, 169, 481-487.	1.1	6
72	Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. Journal of Geriatric Oncology, 2018, 9, 606-612.	0.5	5

#	Article	IF	Citations
73	A plea for appraisal and appreciation of immunohistochemistry in the assessment of prognostic and predictive markers in invasive breast cancer. Breast, 2018, 37, 52-55.	0.9	10
74	Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. Breast Cancer Research and Treatment, 2018, 168, 189-196.	1.1	7
75	Evaluation of the concordance of immunological biomarkers between core biopsy and corresponding resection specimen in ER/PR negative breast cancer. European Journal of Cancer, 2018, 92, S134.	1.3	0
76	Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer. BMC Cancer, 2018, 18, 994.	1.1	9
77	Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. Clinical Drug Investigation, 2018, 38, 1071-1075.	1.1	4
78	Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance. Histopathology, 2018, 73, 923-932.	1.6	21
79	Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. Breast Cancer Research and Treatment, 2018, 171, 1-9.	1.1	37
80	Depleted Uranium and Human Health. Current Medicinal Chemistry, 2018, 25, 49-64.	1.2	61
81	NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2018, 36, 12010-12010.	0.8	2
82	Invasive lobular carcinoma with extracellular mucin productionâ€"a novel pattern of lobular carcinomas of the breast. Clinico-pathological description of eight cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 3-12.	1.4	31
83	Inter-rater reliability in the assessment of stromal characteristics in ductal carcinoma in situ of the breast: how consistent are we?. Breast, 2017, 32, S48-S49.	0.9	0
84	Treatment decision in early stage ER+ HER2â' breast cancer without the 70-gene signature test: a retrospective analysis. Breast, 2017, 32, S130-S131.	0.9	0
85	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. European Journal of Cancer, 2017, 75, 33-40.	1.3	22
86	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€"Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	2.4	530
87	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
88	Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?. Annals of Oncology, 2017, 28, 2317.	0.6	5
89	The footprint of the ageing stroma in older patients with breast cancer. Breast Cancer Research, 2017, 19, 78.	2.2	22
90	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	0.8	14

#	Article	IF	Citations
91	Abstract P2-03-05: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients. , 2017, , .		0
92	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
93	The Baaderâ€“Meinhof phenomenon in ductal carcinoma in situ of the breast. Histopathology, 2016, 69, 522-523.	1.6	5
94	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
95	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
96	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	2.2	43
97	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	2.6	59
98	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. British Journal of Cancer, 2016, 115, 1471-1478.	2.9	45
99	Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. Acta Clinica Belgica, 2016, 71, 383-388.	0.5	24
100	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 473-481.	1.4	11
101	Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. Breast Cancer Research and Treatment, 2016, 155, 603-607.	1.1	6
102	Abstract P5-08-31: Withdrawal of exogenous hormones affects prognostic multigene signature results in early luminal breast cancer. , 2016, , .		0
103	Abstract 5197: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS): a preclinical platform for early drug testing. , 2016, , .		0
104	Investigation of geneâ€environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer, 2015, 136, E685-96.	2.3	34
105	Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. Translational Oncology, 2015, 8, 112-118.	1.7	14
106	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	1.4	40
107	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
108	Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer. Annals of Oncology, 2015, 26, 437-438.	0.6	3

#	Article	IF	Citations
109	P270 Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab. Breast, 2015, 24, S119.	0.9	0
110	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	3.0	99
111	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology, 2015, 26, 259-271.	0.6	2,122
112	Abstract P6-08-05: Prognostic value of the progesterone receptor by proliferation rate in patients with luminal HER2 negative breast cancer. , 2015, , .		0
113	Abstract P6-08-02: The body mass index interacts with the prognostic effect of the progesterone receptor in patients with a luminal HER2 negative breast cancer. , 2015, , .		0
114	Abstract 1461: A panel of patient derived gastrointestinal stromal tumors (GIST) xenograft models for in vivo preclinical drug testing. , 2015, , .		0
115	Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. Modern Pathology, 2014, 27, 1510-1520.	2.9	27
116	Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research, 2014, 20, 6071-6082.	3.2	45
117	Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Breast, 2014, 23, 453-459.	0.9	15
118	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32
119	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	2.9	21
120	A Negative Progesterone Receptor in Luminal Her-2 Negative Breast Cancer by Age at Diagnosis: 10 Years Follow-Up. Annals of Oncology, 2014, 25, i8.	0.6	0
121	Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. Clinical Sarcoma Research, 2014, 4, 10.	2.3	24
122	Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. Breast, 2014, 23, 371-377.	0.9	10
123	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
124	Is the sentinel lymph node biopsy more sensitive for the identification of positive lymph nodes in breast cancer than the axillary lymph node dissection?. SpringerPlus, 2013, 2, 275.	1.2	1
125	Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer. SpringerPlus, 2013, 2, 480.	1.2	11
126	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201

#	Article	IF	Citations
127	The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. Breast, 2013, 22, 254-262.	0.9	7
128	A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Annals of Oncology, 2013, 24, 47-53.	0.6	40
129	Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. Annals of Oncology, 2013, 24, 1847-1852.	0.6	34
130	A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clinical Cancer Research, 2013, 19, 620-630.	3.2	64
131	Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis?. ISRN Immunology, 2013, 2013, 1-5.	0.7	8
132	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052.. Journal of Clinical Oncology, 2013, 31, 10573-10573.	0.8	2
133	Efficacy of the phosphoinositol 3 kinase (PI3K) inhibitor GDC-0941 in patient- and cell-line-derived xenografts of dedifferentiated liposarcoma (DDLPS).. Journal of Clinical Oncology, 2013, 31, e13528-e13528.	0.8	0
134	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Annals of Oncology, 2012, 23, 2578-2584.	0.6	46
135	Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis. Journal of Pathology, 2012, 228, 565-574.	2.1	14
136	Sentinel Lymph Node Involvement in Ductal Carcinoma In-Situ of the Breast: Two Different Causes. Clinical Breast Cancer, 2012, 12, 378-381.	1.1	0
137	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
138	Update on triple-negative breast cancer: prognosis and management strategies. International Journal of Women's Health, 2012, 4, 511.	1.1	91
139	Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models.. Journal of Clinical Oncology, 2012, 30, 10030-10030.	0.8	2
140	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptorâ€“Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
141	The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics, 2011, 10, 1897-1908.	1.9	43
142	Frequent activation of EGFR in advanced chordomas. Clinical Sarcoma Research, 2011, 1, 4.	2.3	36
143	Intrinsic cell memory reinforces myogenic commitment of pericyteâ€derived iPSCs. Journal of Pathology, 2011, 223, 593-603.	2.1	71
144	The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations. Clinical Cancer Research, 2011, 17, 5604-5614.	3.2	48

#	Article	IF	Citations
145	IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis. PLoS ONE, 2011, 6, e19846.	1.1	41
146	Coactivated Platelet-Derived Growth Factor Receptor Î± and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. Cancer Research, 2010, 70, 7304-7314.	0.4	80
147	Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14333-14338.	3.3	194
148	Implications of Mutational Analysis for the Management of Patients With Gastrointestinal Stromal Tumors and the Application of Targeted Therapies. Cancer Investigation, 2010, 28, 839-848.	0.6	16
149	Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib.. Journal of Clinical Oncology, 2010, 28, 10020-10020.	0.8	3
150	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. Clinical Cancer Research, 2009, 15, 4066-4076.	3.2	53
151	Assessment of the heat shock protein 90 (HSP90) inhibitor IPI504 alone or in combination with the tyrosine kinase inhibitor (TKI) imatinib in mice carrying xenografts of human gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology, 2009, 27, 10534-10534.	0.8	3
152	Malignant Ectomesenchymoma: Genetic Profile Reflects Rhabdomyosarcomatous Differentiation. Diagnostic Molecular Pathology, 2007, 16, 243-248.	2.1	19
153	Tyrosine kinases as possible therapeutic targets in pulmonary artery intimal sarcoma. Journal of Clinical Oncology, 2007, 25, 10055-10055.	0.8	0
154	A rare case of vagus nerve schwannoma. Chirurgia Italiana, 2007, 59, 907-10.	0.2	0
155	Epithelioid Hemangioma of Bone: A Potentially Metastasizing Tumor?. International Journal of Surgical Pathology, 2006, 14, 9-15.	0.4	30
156	A metabolic approach to the treatment of dilated cardiomyopathy in BIO T0â€“2 cardiomyopathic Syrian hamsters. BioFactors, 2005, 25, 127-135.	2.6	5
157	Indications and limits of palliative resection for gastric cancer: our experience. Journal of Chemotherapy, 1999, 11, 224-226.	0.7	1
158	Production of antibodies against the coenzyme pyrrolequinoline quinone. FEBS Letters, 1989, 247, 201-204.	1.3	25